Fusacandins A and B; Novel Antifungal Antibiotics of the Papulacandin Class from Fusarium sambucinum. I. Identity of the Producing Organism, Fermentation and Biological Activity.

Jackson, Marianna; Frost, David J.; Karwowski, James P.; Humphrey, Patrick E.; Dahod, Samun K.; Choi, Won Sik; Brandt, Kim; Malmberg, Li Hong; Rasmussen, Ronald R.; Scherr, Michael H.; Flamm, Robert K.; Kadam, Sunil; McAlpine, James B.

doi:10.7164/antibiotics.48.608

Cited by 17 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The WF11899 group containing WF11899 A, B, and C have demonstrated anti- Candida activities in vivo in a murine model of systemic infection and were more effective than cliofungin or fluconazole [86]. Papulacandin analogs include: a) corynecandin [87] isolated from cultures of Coryneum modonium , a glycolipid analogous to the structural variant of papulacandin named chaetiacandin, b) Mer-WF3010, isolated from the culture broth of Phialophora cyclaminis [88], and c) fusacandin, another structural variant of chaetiacandin isolated from Fusarium sambucinum [89]. Fusacandin is a trisaccharide and unlike the other analogs which are disaccharides, has demonstrated poor activity in animal models, prompting attempts to find analogs with improved activity in vivo using structure–activity relationship (SAR) studies [90].…”

Section: Fungal Cell Wall As a Drug Development Targetmentioning

confidence: 99%

The Mechanistic Targets of Antifungal Agents: An Overview

Mazu¹,

Bricker²,

Flores‐Rozas³

et al. 2016

MRMC

168

View full text Add to dashboard Cite

Pathogenic fungi are a major causative group for opportunistic infections (OIs). AIDS patients and other immunocompromised individuals are at risk for OIs, which if not treated appropriately, contribute to the mortality associated with their conditions. Several studies have indicated that the majority of HIV-positive patients contract fungal infections throughout the course of their disease. Similar observations have been made regarding the increased frequency of bone marrow and organ transplants, the use of antineoplastic agents, the excessive use of antibiotics, and the prolonged use of corticosteroids among others. In addition, several pathogenic fungi have developed resistance to current drugs. Together these have conspired to spur a need for developing new treatment options for OIs. To aid this effort, this article reviews the biological targets of current and emerging drugs and agents that act through these targets for the treatment of opportunistic fungal infections.

show abstract

Section: Fungal Cell Wall As a Drug Development Targetmentioning

confidence: 99%

The Mechanistic Targets of Antifungal Agents: An Overview

Mazu¹,

Bricker²,

Flores‐Rozas³

et al. 2016

MRMC

168

View full text Add to dashboard Cite

show abstract

“…This group of myco‐metabolites consists of B2 64, F‐10748 A2 63, and D2 66 from P. sphaerosperma , corynecandin 68 from Coryneum modonium , and chaetiacandin 67 from Monochaetia dimorphospora [79]. Fusacandin B 70 and A 69 also constitute a reduced spiroketal; however, they are exclusive because of the presence of an extra galactose to the already galactose unit [80]. Corynecandin 68 and chaetiacandin 67 are only papulacandins having a short fatty acid chain attached with the glucose unit.…”

Section: Myco‐metabolites Effective Against Biofilm Infectionsmentioning

confidence: 99%

New holistic approach for the management of biofilm‐associated infections by myco‐metabolites

et al. 2022

View full text Add to dashboard Cite

Biofilm‐associated infections have increased excessively over the recent years due to the increased population having impaired immune systems or as a result of certain medical conditions like transplantation, cancer, and any other chronic ailments. The abrupt enhancement of antibiotic resistance and enhanced utilization of biomedical devices offer new opportunities for microbial colonization leading to the development of microbial biofilms. Total eradication of recalcitrant microbial biofilms demands the adoption of a holistic approach and since the fungal metabolites enriched with bioactive compounds show efficacy in inhibiting the multiple factors behind biofilm formation, the anti‐biofilm activities of fungal metabolites need to be appraised. Being effective in preventing various steps of biofilm formation, including inhibition of surface adhesion and cell‐to‐cell communication through quorum quenching, blocking of quorum sensing receptors, and enzymes involved in microbial cell wall biosynthesis, targeting the virulence factors and finally killing of biofilm bound individual cells; myco‐metabolites are found effective as a potent holistic anti‐biofilm agent. The wide spectrum of bioactive substances of fungi and their anti‐biofilm activities against different pathogens and their multitarget characteristics are very promising in the field of treating biofilm infections.

show abstract

“…To this group of secondary metabolites belong F-10748 A2 63, B2 64, C2 65, and D2 66, also from Papularia sphaerosperma, chaetiacandin 67 from Monochaetia dimorphospora [100,101], and corynecandin 68 from Coryneum modonium [102]. Fusacandin A 69 and B 70 have also such a reduced spiroketal, but they are unique due to the attachment of an additional galactose to the galactose unit [103,104] (Figure 7). Chaetiacandin 67 and corynecandin 68 are the only papulacandins with a shortened fatty acid at the glucose unit.…”

Section: From Papulacandins and Echinocandins To Drugs Against Fungalmentioning

confidence: 99%

Fungal Metabolites for the Control of Biofilm Infections

Estrela

Abraham

2016

Agriculture

View full text Add to dashboard Cite

Many microbes attach to surfaces and produce a complex matrix of polymers surrounding their cells, forming a biofilm. In biofilms, microbes are much better protected against hostile environments, impairing the action of most antibiotics. A pressing demand exists for novel therapeutic strategies against biofilm infections, which are a grave health wise on mucosal surfaces and medical devices. From fungi, a large number of secondary metabolites with antimicrobial activity have been characterized. This review discusses natural compounds from fungi which are effective against fungal and bacterial biofilms. Some molecules are able to block the cell communication process essential for biofilm formation (known as quorum sensing), others can penetrate and kill cells within the structure. Several targets have been identified, ranging from the inhibition of quorum sensing receptors and virulence factors, to cell wall synthesizing enzymes. Only one group of these fungal metabolites has been optimized and made it to the market, but more preclinical studies are ongoing to expand the biofilm-fighting arsenal. The broad diversity of bioactive compounds from fungi, their activities against various pathogens, and the multi-target trait of some molecules are promising aspects of fungal secondary metabolites. Future screenings for biofilm-controlling compounds will contribute to several novel clinical applications.

show abstract

Fusacandins A and B; Novel Antifungal Antibiotics of the Papulacandin Class from Fusarium sambucinum. I. Identity of the Producing Organism, Fermentation and Biological Activity.

Cited by 17 publications

References 12 publications

The Mechanistic Targets of Antifungal Agents: An Overview

The Mechanistic Targets of Antifungal Agents: An Overview

New holistic approach for the management of biofilm‐associated infections by myco‐metabolites

Fungal Metabolites for the Control of Biofilm Infections

Contact Info

Product

Resources

About